Drug intelligence / Profile preview

Viveta

Development stage: Unknown
Lead developer: United Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

Viveta is a topical anesthetic cream containing a combination of lidocaine (7% w/w) and tetracaine (7% w/w). Manufactured by Ajanta Pharma, it is used to provide local anesthesia for minor dermatological and surgical procedures, including laser treatments, tattoo removal, dermal filler injections, and skin biopsies. The mechanism of action involves the reversible blockade of voltage-gated sodium channels in nerve fibers, which inhibits the ionic fluxes required for the initiation and conduction of pain impulses. Following topical application, the cream typically induces numbness within the treated area that lasts for approximately one to two hours.

Brand names: Viveta
Other names: Viveta Cream

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Viveta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viveta.

Explore the full profile